Cite
HARVARD Citation
Smith, T. et al. (2021). STOP 301: A Phase 3, open‐label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD®) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. Headache. 61 (8), pp. 1214-1226. [Online].